DEVELOP LIVE ATTENTUATED COLD ADAPTED INFLUENZA VACCINE

开发冷适应流感减毒活疫苗

• 批准号: 2294533
• 负责人: H F MAASSAB
• 金额: $ 35.44万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-10-25 至 1992-10-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2294533
• 关键词: DEVELOP; LIVE; ATTENTUATED; COLD; ADAPTED

The objectives of the contract involve the establishment of procedures for the preparation and characterization of live, attenuated, cold- adapted (ca) influenza A and B virus reassortants for use as vaccines. Under the direction of the Project Officer, this laboratory will be a repository for clinical samples from primary field isolates and will evaluate them for potential use as hemagglutinin and neuraminadase donors for the vaccine strains. The Contractor will be responsible for the management, retrieval, analysis, validation and publication of data and the cataloguing, storage, and shipment of the wild-type and reassortant influenza A and B viruses required for the studies. Using a ferret model, the reassortant clones will be characterized as to phenotypic and genotypic stability, virulence, and reactogenicity including the determination of the appropriate dose and schedule for intranasal administration of trivalent ca reassortant vaccines. In addition, the Contractor will supply vaccine clones for distribution to other investigators as requested by the Project Officer and will characterize virus isolated from subjects in clinical tests. Molecular analyses will be conducted in order to further characterize the ca parent viruses and compare them to their wild-type progenitors. Investigations will continue into the mechanisms by which certain of the reassortant vaccine strains become reactogenic in an attempt to better predict the behavior of the vaccine strains in humans.

合同的目标包括建立程序 用于制备和表征活的、减毒的、冷的 适于用作疫苗的（ca）甲型和B型流感病毒抑制剂。 在项目官员的指导下，该实验室将是一个 储存来自主要田间分离株的临床样本， 评估它们作为血凝素和神经氨酸苷酶的潜在用途 疫苗株的捐赠者 承包商将负责 数据的管理、检索、分析、验证和发布 以及野生型和 重配 研究所需的甲型和B型流感病毒。 使用 雪貂模型，抗性克隆将被表征为 表型和基因型稳定性、毒力和反应原性 包括确定适当的剂量和时间表， 鼻内施用三价预防性疫苗。 在 此外，承包商将提供疫苗克隆， 项目官员要求的其他调查人员， 在临床试验中表征从受试者中分离的病毒。 分子 将进行分析，以进一步描述病例的特征。 亲本病毒，并将它们与它们的野生型祖先进行比较。 将继续调查某些国家和国际组织 为了更好地预防流感， 预测疫苗株在人体内的行为。